本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
NEW YORK, March 13, 2025 /PRNewswire/ -- Today, Shawn "JAY-Z" Carter's legal team announced that ABC News obtained and unveiled a new recording from Jane Doe that confirmed that Carter never sexually assaulted her and that lawyer Tony Buzbee urged Doe to make false allegations against Carter. The recorded conversation, which took place between Doe and private investigators, included the groundbreaking excerpt outlined: Investigator #1: So you only got into JAY-Z's name because he was asking you and – did he suggest that JAY-Z might have had some part in it? Jane Doe: He was the one that kind of pushed me towards going forward with him, with JAY-Z. Investigator #2: With JAY-Z? Buzbee did? Jane Doe: Yeah The new audio reaffirms the evidence that Carter's legal team submitted to the Superior Court of the State of California earlier in March, which included two sworn declarations from Butler and Henderson that showed Buzbee pushed his client to lie. Furthermore, the recording shows that Doe admitted that Carter never sexually assaulted her: Investigator #1: [Buzbee] asked you about JAY-Z? Jane Doe: Yeah Investigator #1: But JAY-Z, was you're saying, he was definitely there? But he had no part in it, or he was just – Jane Doe: He was there Investigator #2: He was just there, but he didn't have anything to do with any sexual acts towards you, it was strictly – Jane Doe: Yeah In an interview with ABC News, Carter's attorney Alex Spiro explained that "the tape speaks for itself" and "it's effectively a lie and the only reason Mr. Carter is even involved in this is because she was pushed to involve him." The development comes one day after Buzbee was reprimanded by Judge Ronnie Abrams in an order that confirmed that Buzbee filed a complaint and other pleadings in the Southern District of New York despite not being admitted to practice there. He also failed to disclose the violation despite a previous warning from another judge.
BEIJING, March 8, 2025 /PRNewswire/ -- A news report from chinadaily.com.cn： The intensified multilateral and bilateral exchanges between China and other countries and regions have led to an increase in foreign-related legal cases in the country, which has made the importance and urgency of strengthening foreign-related procuratorial work more prominent, said Ying Yong, prosecutor-general of the Supreme People's Procuratorate. As high-level opening-up further advances, an increasing number of Chinese enterprises and citizens are venturing into the world, and China's development interests are expanding overseas at a faster pace. As a result, the country has witnessed an increase in the number, types and areas of foreign-related legal cases, and the demand for legal support from the State, enterprises, and citizens is growing, posing new and higher requirements for strengthening foreign-related procuratorial work, Ying, prosecutor-general of the SPP, said in an exclusive interview with China Daily, on the sidelines of the ongoing two sessions. Also, foreign-related procuratorial work will attach great importance to combating transnational economic crimes, especially money laundering, illegal foreign exchange transactions, counterfeiting and infringement of intellectual property rights, to foster a world-class and market-oriented business environment supported by a sound legal framework, Ying said. "We will equally protect the legitimate rights and interests of various domestic and foreign business entities in accordance with the law," Ying said. "We will uphold equal protection of various types of economic entities involving both domestic and foreign capital in line with the law, and hold those who infringe upon the property rights and legitimate interests of various economic entities equally accountable." He said foreign-related procuratorial work is an important duty of procuratorial organs, a vital part of prosecution work, and an important aspect of the country's foreign-related rule of law. Since the 18th National Congress of the Communist Party of China in 2012, the CPC Central Committee has attached great importance to foreign-related rule of law and made a series of major decisions and plans. On Nov 14, the national conference on foreign-related procuratorial work was held in Shanghai, marking the first meeting convened by the SPP specially dedicated to foreign-related procuratorial work. In December, the SPP also published a guideline on strengthening foreign-related procuratorial work, based on broad research and investigation and extensive consultations, to effectively enhance the quality and efficiency of related work. "Foreign-related procuratorial work must effectively shoulder a heavier responsibility in serving high-quality development and opening-up, more forcefully safeguarding the country's development interests, as well as protecting the legitimate rights and interests of Chinese enterprises and citizens," Ying said. Meanwhile, foreign-related procuratorial work also aims to lawfully safeguard the legitimate rights and interests of various entities such as Chinese citizens and enterprises overseas. Prosecutorial authorities will coordinate with relevant departments to help enterprises solve legal issues abroad, and promote the better use of legal tools by overseas enterprises to safeguard their legitimate rights and interests, Ying said. "By strengthening coordination among different departments and enforcing international judicial cooperation, we will jointly build a strong legal support chain to protect China's overseas interests, and protect the legitimate rights and interests and production and living order of various entities such as Chinese citizens and enterprises overseas," he said. As noted by Ying, procuratorial work will also better serve high-quality development of the Belt and Road Initiative by strengthening communication, exchanges and information sharing with procuratorial organs in countries taking part in the BRI. Efforts will also be made to continuously implement procuratorial policies that support and guarantee the development of free-trade zones and the Hainan Free Trade Port. Furthermore, procuratorial authorities will further deepen international judicial exchanges and cooperation as judicial exchanges and cooperation are a crucial part of major-country diplomacy with Chinese characteristics, Ying said. "We have actively promoted high-level mutual visits among procuratorial authorities to expand the circle of friends," Ying said. On Oct 28, Ying called for procuratorial authorities in China and the Association of Southeast Asian Nations to increase exchanges and cooperation, during his speech delivered at the opening of the 14th China-ASEAN Prosecutors General Conference held in Singapore. Also, meetings and exchanges with prosecutors-general and chairmen of judicial committees of more than 20 countries have been held in 2024. So far, the SPP has signed bilateral cooperation agreements with law enforcement and judicial agencies in 100 countries and regions worldwide. Ying said procuratorial authorities will enhance practical cooperation with foreign prosecutorial authorities in combating transnational crimes and further intensify efforts to combat cross-border telecommunications fraud crimes. "We will vigorously crack down on violent terrorist forces, ethnic separatist forces and religious extremist forces, and jointly punish international drug trafficking, cross-border gambling, online terrorist activities, telecommunications fraud, cross-border human trafficking, illegal border crossings and cross-border illegal sand mining," he said. In April last year, the SPP, together with six other departments, jointly formulated the Provisions on Several Issues Concerning the Implementation of the International Criminal Judicial Assistance Law of the People's Republic of China, further standardizing procedures for international criminal judicial assistance. After its implementation, 293 criminal judicial assistance cases were handled last year. He added that it's necessary to actively participate in the formulation of foreign-related laws and regulations, as well as international rules. "We will actively join discussions on important issues in international organizations and institutions, engage in the formulation of international rules in areas such as ecological environment protection, financial regulation, cyber governance, intellectual property protection, international economic and trade, as well as negotiations on criminal judicial assistance, extradition, and the transfer of sentenced persons treaties," Ying said. In 2024, the SPP participated in negotiations and consultations on the United Nations Convention against Cybercrime and three criminal judicial assistance treaties.
Most Resolutions from Korea Zinc's Extraordinary Shareholders' Meeting Suspended… A Big Win for Young Poong and MBK Partners A Green Light for Securing Control Over Korea Zinc SEOUL, South Korea, March 8, 2025 /PRNewswire/ -- The court has ruled that restricting Young Poong's voting rights at Korea Zinc's extraordinary shareholders' meeting on January 23 was unlawful, suspending the effectiveness of most resolutions passed, including the resolution to impose a cap on the number of directors. Furthermore, as Young Poong's voting rights restriction was deemed illegal, the duties of the seven Korea Zinc-nominated directors, who were appointed through a process marred by significant procedural defects, have also been suspended. On March 7, the Seoul Central District Court's Civil Division 50 granted Young Poong and MBK Partners' injunction request to suspend the resolutions of Korea Zinc's extraordinary shareholders' meeting, ruling that "Under Article 369, Paragraph 3 of the Commercial Act, restricting Young Poong's voting rights in Korea Zinc is unlawful." The court consequently suspended the effectiveness of the resolutions on: Article 1-2: Establishing a cap on the number of directorsArticle 1-4: Stock splitArticle 1-6: Appointment of the board chair from among outside directorsArticle 1-7: Amendment of the dividend record dateArticle 1-8: Introduction of quarterly dividends Additionally, the seven directors nominated by Korea Zinc have been prohibited from exercising their duties as outside directors. With this ruling, while the resolution to amend the articles of incorporation to introduce cumulative voting (Article 1-1) remains effective, the cap on the number of directors (set at 19) has been nullified, and the seven Korea Zinc-nominated directors can no longer perform their duties. This decision paves the way for Young Poong and MBK Partners, the largest shareholders, to secure control over Korea Zinc. Young Poong and MBK Partners welcomed the court's decision to grant the injunction. At Korea Zinc's annual general meeting, expected in late March, a new board of directors will be elected through cumulative voting. Young Poong and MBK Partners have already submitted a shareholder proposal nominating 17 director candidates. A representative from Young Poong and MBK Partners stated, "We will make every effort to restore corporate governance, shareholder value, and corporate value at Korea Zinc through a fair and transparent annual general meeting."
Court awards $10M to KPM Analytics in Trade Secret Theft and Tortious Interference Case, Reinforcing Commitment to Innovation and Fair Competition. WESTBOROUGH, Mass., March 3, 2025 /PRNewswire/ -- KPM Analytics, a global leader in analytical instrumentation for food and agriculture industries, has been awarded damages, attorney fees, and interest, totaling just over $10 million in a decisive legal victory against Blue Sun Scientific, LLC, the Innovative Technologies Group & Co., Ltd., and certain ex-KPM employees. In addition to the awarded monetary damages, the United States District Court for the District of Massachusetts also granted KPM Analytics' requests for a permanent injunction against the defendants, including Blue Sun Scientific, LLC, prohibiting the defendants from offering to sell certain NIR products, services, hardware, software, or data to customers. The 11-day trial of KPM Analytics North America Corporation vs. Blue Sun Scientific, LLC, The Innovative Technologies Group & Co., Ltd., Arnold Eilert, Robert Gajewski, Rachael Glenister, and Irvin Lucas (Civil Action No. 21-CV-10572-MRG), which concluded with a unanimous verdict on 6 counts of the Complaint against the defendants on May 17, 2023, stemmed from allegations that the defendants willfully and maliciously misappropriated confidential information and trade secrets concerning KPM Analytics near infrared (NIR) technologies. As a result, the court awarded exemplary damages, doubling the compensatory damages against certain defendants. "This verdict is not just a win for KPM Analytics but for the entire industry," said Brian Mitchell, Chief Executive Officer for KPM Analytics. "Innovation is the backbone of our business, and we will always take the necessary steps to protect our proprietary technology from unlawful use." KPM would like to extend its gratitude to the dedicated legal team, Sunstein LLP and Morse Barnes-Brown & Pendleton, PC, expert witnesses, and all those involved in the two-year long case, whose unwavering support and diligent efforts were instrumental in achieving this significant victory. The verdict serves as a reminder that KPM will not tolerate the misappropriation of its trade secrets and will take all necessary legal measures to safeguard its valuable intellectual property. About KPM Analytics KPM Analytics is a global leader in scientific instrumentation and vision process machinery, focused primarily on analyzing critical parameters within the food, feed, agriculture, and environmental sectors. We provide a comprehensive range of products and services to uniquely solve our customers' problems. Our brands include AMS Alliance, Bruins Instruments, CHOPIN Technologies, EyePro System, Process Sensors, Sensortech, Sightline, Smart Vision Works, and Unity Scientific. Each has a long history of delivering advanced and reliable analysis solutions to ensure product quality and optimize process efficiency, with customer service at the center of everything we do. Visit www.kpmanalytics.com to learn more. Media contacts: Andy Dambeck Marketing Manager adambeck@kpmanalytics.com 774-399-0477
SINGAPORE, Feb. 28, 2025 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company") today issued a statement addressing a recent decision by the Singapore International Commercial Court ("SICC"), which granted an injunction sought by Novo Nordisk A/S ("Novo Nordisk") against the Company and its founder, Dr. Huang Zhenhua ("Dr. Huang") on February 14, 2025. The SICC decision was issued on an ex parte basis without the knowledge or participation of the Company and Dr. Huang. Novo Nordisk filed the application after it announced on June 26, 2024 that it was stopping CLARION-CKD trial for Ocedurenone, a drug for uncontrolled hypertension and advanced chronic kidney disease (CKD) that it acquired from the Company in 2023. "We are disappointed by Novo Nordisk's conduct in seeking the injunction without notice to us, which meant that we were not given the opportunity to defend ourselves in court. The serious allegations made by Novo Nordisk are completely unfounded and the truth will vindicate us in time to come. There is tremendous potential in Ocedurenone, and we remain committed to its cause," said Dr. Huang Zhenhua, founder and chairman of the Company. The Company and Dr. Huang will have an opportunity to be heard by the Singapore courts and have engaged legal counsel to vigorously defend their legal rights. All media inquiries can be directed to: info@kbpbiosciences.com About KBP Biosciences Pte. Ltd. KBP Biosciences is a global, clinical-stage biotechnology company, headquartered in Singapore, focused on discovering, developing, and commercializing innovative small-molecule therapeutics for the treatment of serious cardiorenal and infectious diseases with large unmet medical needs. About Ocedurenone (KBP-5074) Ocedurenone is a third-generation, non-steroidal, mineralocorticoid receptor antagonist (MRA) with a unique pharmacokinetic (PK) profile characterised by a long half-life and high mineralocorticoid receptor (MR) affinity. Certain MRAs have shown benefits in people with hypertension or heart failure, as well as cardiorenal benefits in patients with chronic kidney disease (CKD) and type 2 diabetes [1]. [1] Kintscher U, et al. Br J Pharmacol. 2022 Jul;179(13):3220-3234. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease - PubMed (nih.gov) For more information about KBP Biosciences, please visit the company website at https://www.kbpbiosciences.com/
HKGI Partners with Global Leaders to Chart a Course for Healthcare Transformation HONG KONG, Feb. 19, 2025 /PRNewswire/ -- Genomic medicine has been gaining global prominence for its vast potential to revolutionise healthcare services. In the case of rare conditions, genomic medicine has been particularly transformative, as approximately 80% of rare diseases are of genetic origin. Genomic medicine has the power to facilitate diagnosis and access to curative and life-changing treatments for people living with these rare conditions. Now, Hong Kong is set to partner with world-renowned authorities to drive exchanges dedicated to this burgeoning field, taking advantage of the city's unique strengths in medical research and development. The Hong Kong Genome Institute (HKGI), Rare Diseases International (RDI), and The Lancet Commission on Rare Diseases (LCRD) will join forces for the first time to organise the International Genomic Medicine Symposium (Symposium) on 17 November 2025 (Monday) at the Hong Kong Science Park. This landmark event will convene distinguished experts, clinicians and scientists from over 20 countries and regions to foster knowledge exchanges in genomic medicine and rare diseases, representing a significant collaboration among leading institutions committed to accelerating the development of genomic medicine on a global scale and providing an unparalleled opportunity to improve outcomes for the 300 million persons living with a rare disease worldwide. The Symposium, focusing on the latest advancements and trends in genomic medicine, features a robust lineup of local and international experts in genetics and genomics, including Dr Chloe Wilson, Senior Medical Editor of The Lancet, one of the world's most authoritative academic journals. This diverse group of experts is poised to exchange insights on a wide range of topics – from rare diseases to cancer detection and molecular diagnoses; from genomic data sharing to legal and ethical discussions; and from artificial intelligence (AI) to healthcare record management and scientific research. The Opening Ceremony will be officiated by Professor Lo Chung-mau, Secretary for Health of the Hong Kong SAR Government. Setting the stage, Professor Lo will deliver a keynote address, laying the groundwork for a deep dive into genomic innovations and clinical applications. Dr Lo Su-vui, Chief Executive Officer of HKGI, and Alexandra Heumber Perry, Chief Executive Officer of RDI, will also join the Opening Ceremony to unveil the event. Highlights of esteemed speakers include: Professor Dennis Lo, Vice-Chancellor and President of The Chinese University of Hong Kong, as well as Board Member of HKGI, will discuss cutting-edge applications of plasma DNA analysis. Dr Brian Chung, Chief Medical and Scientific Officer of HKGI, will share the journey of implementing Hong Kong Genome Project, the city's first large-scale whole genome sequencing (WGS) initiative aimed at propelling personalised medicine forward. Professor Zhang Shuyang, President of the Peking Union Medical College Hospital and pioneer in Mainland China's rare diseases programmes, will introduce respective models covering teaching, service and research. Professor Kym Boycott from the University of Ottawa (Canada) will focus on molecular pathogenesis of rare diseases that improve patient care and family well-being. Professor Roberto Giugliani from the Federal University of Rio Grande do Sul (Brazil) and a leading researcher in Latin American genetics, will share his perspectives on metabolic disorders. Professor Bartha Maria Knoppers from McGill University (Canada) and an expert in genomics and biotechnology ethics, will discuss legal topics arising from genomic data sharing. Professor Gareth Baynam from the Perth Children's Hospital (Australia), and Professor Yong Chen from the University of Pennsylvania (USA) will also offer insights on harnessing the latest technologies such as AI for clinical and healthcare records to inspire innovation. Dr Lo Su-vui, Chief Executive Officer of HKGI said, "We are greatly honoured and excited to partner with RDI and LCRD, two world-leading institutions that share our vision of making genomic medicine available to all for better health and well-being. This Symposium, rich in depth and scope, marks a pivotal milestone in advancing genomic medicine through international collaborations. By bringing together global experts and showcasing Hong Kong's capabilities in genomic research and clinical applications, we are not only reaffirming our commitment to integrating genomics into routine patient care and inspiring ground-breaking research, but also contributing to Hong Kong's development as an International Health and Medical Innovation Hub." Alexandra Heumber Perry, Chief Executive Officer of RDI added, "We are thrilled to partner with the Hong Kong Genome Institute on this important initiative to advance research on rare diseases and improve outcomes for Persons Living with Rare Diseases (PLWRD) around the world. This Symposium, which will bring together leading experts from more than 20 countries and regions, demonstrates our joint commitment to placing PLWRD at the centre of their own care, and to promoting health equity, human rights and access to treatment for PLWRD. Through the shared dedication and expertise of the experts from the RDI-LCRD and HKGI, we will work to ensure that PLWRD are seen, heard and cared for, no matter where they live." The one-day Symposium is anticipated to attract close to 300 participants. For programme details, please refer to the Appendix. Following the Symposium, the annual LCRD Meeting will be held on 18-19 November 2025, which will further strengthen international cooperations in research and development of genomic medicine and rare diseases. For enquiries about the Symposium, please contact: HKGI (symposium@genomics.org.hk) or RDI-LCRD (lcrd@rarediseasesint.org). About Hong Kong Genome Institute The Hong Kong Genome Institute (HKGI), established and wholly owned by the Hong Kong SAR Government, commenced full operations in 2021. With the vision "to avail genomic medicine to all for better health and well-being" and supported by the Health Bureau, HKGI works in close collaboration with the Department of Health, Hospital Authority, medical schools of local universities and other stakeholders to accelerate the development of genomic medicine in Hong Kong along four strategic foci: integrate genomics into medicine, advance research, nurture talents and enhance public genomic literacy. As the first step towards achieving its vision, HKGI launched the Hong Kong Genome Project (HKGP) in 2021 focusing on diseases and research cohorts that would benefit from whole genome sequencing. They include undiagnosed diseases, hereditary cancers and cases related to genomics and precision health. Being the city's first large-scale genome sequencing project, HKGP serves as a catalyst to benefit patients and their families with more precise diagnosis and personalised treatment. It also aims to establish genome database of the local population, testing infrastructure and talent pool to address the healthcare needs of Hong Kong in the long run. For more information, please visit https://hkgp.org/en. About Rare Diseases International Rare Diseases International (RDI) is the global alliance of people living with a rare disease of all nationalities across all rare diseases. RDI's mission is to be a strong common voice on behalf of rare disease patients around the world, to advocate for rare diseases as an international public health priority and to represent its members and enhance their capacities. RDI has more than 120 member organizations from 50 countries, which in turn represent rare disease patient groups in more than 150 countries worldwide. For more information, please visit https://www.rarediseasesinternational.org. About Lancet Commission on Rare Diseases The RDI-Lancet Commission on Rare Diseases (RDI-LCRD) is a new initiative dedicated to improving the lives of Persons Living with a Rare Disease (PLWRD) globally by generating evidence-informed recommendations that can be implemented in all countries. The RDI-LCRD, chaired by Dr. Roberto Giugliani (Brazil) and Dr. Kym Boycott (Canada) brings together 27 Commissioners from 6 continents with a broad range of expertise, perspectives and experience. The overarching goal of the RDI-LCRD is to use robust data to ignite global action that will amplify the voices of PLWRD and ensure that they are seen, heard, and cared for, no matter where they live. For more information, please visit http://www.rarediseasescommission.org. International Genomic Medicine Symposium 17 November 2025, Hong Kong Charles K. Kao Auditorium, Hong Kong Science Park Time Programme Speaker 09:00 Keynote Prof Lo Chung-mau, BBS, JP Secretary for Health Hong Kong SAR Government Hong Kong, China 09:15 Opening Ceremony Panel 1 09:30 Developing Rare Disease Models in China: Service, Teaching and Research Prof Zhang Shuyang President Peking Union Medical College Hospital China 10:00 Unraveling Molecular Pathogeneses to Enhance Patient Care and Family Well-being Prof Kym Boycott Co-Chair Lancet Commission on Rare Diseases Professor of Pediatrics University of Ottawa Canada 10:30 Panel Discussion 10:45 Coffee Break Panel 2 11:15 Insights into Rare Diseases: Focus on Inborn Errors of Metabolism Prof Roberto Giugliani Professor of Genetics Federal University of Rio Grande do Sul Brazil 11:45 Hong Kong Genome Project Case Sharing (1): Ending the Diagnostic Odyssey Hong Kong College of Physicians – Hong Kong Genome Institute Scholar Hong Kong, China 12:00 Hong Kong Genome Project Case Sharing (2): Whole Genome Sequencing Informs Personalised Treatment Hong Kong Academy of Medicine –Hong Kong Genome Institute Scholar Hong Kong, China 12:15 Panel Discussion 12:30 Lunch Panel 3 14:00 Exploring Ethico-legal Issues in Genomic Data Sharing Prof Bartha Knoppers Director Centre of Genomics and Policy McGill University Canada 14:30 Hong Kong Genome Project: Advancing the Genomics Frontier Dr Brian Chung Chief Medical and Scientific Officer Hong Kong Genome Institute Hong Kong, China 15:00 Facilitating Drug Development in the Greater Bay Area International Clinical Trial Institute (GBAICTI) GBAICTI Representative Hong Kong, China 15:30 Panel Discussion Panel 4 15:45 AI in Action: The Journey from Clinical Record to Personalised Treatment Prof Gareth Baynam Medical Director Rare Care Centre Perth Children's Hospital Australia 16:15 Harnessing the Power of Electronic Healthcare Records in Scientific Research and Innovation in Genomic Medicine Prof Yong Chen Professor of Biostatistics University of Pennsylvania USA 16:45 Panel Discussion Panel 5 17:00 Publishing at The Lancet Dr Chloe Wilson Senior Medical Editor The Lancet 17:30 Keynote: Revolutionising Plasma DNA Analysis in Transforming Non-invasive Testing and Cancer Detection Prof Dennis Lo, SBS, JP Vice-Chancellor and President The Chinese University of Hong Kong Board Member Hong Kong Genome Institute Hong Kong, China 18:00 Panel Discussion 18:15 End of Symposium Enquiry Hong Kong Genome Institute www.hkgp.org symposium@genomics.org.hk Rare Disease International www.rarediseasesinternational.org lcrd@rarediseasesint.org
A12 藝術空間
Legal issues
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
